Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW)

Bank of New York Mellon Corp boosted its position in Harrow, Inc. (NASDAQ:HROW) by 8.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,447 shares of the company’s stock after buying an additional 6,690 shares during the period. Bank of New York Mellon Corp owned approximately 0.24% of Harrow worth $2,900,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new stake in Harrow in the 3rd quarter valued at $29,000. China Universal Asset Management Co. Ltd. boosted its holdings in Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after purchasing an additional 727 shares during the period. Virtu Financial LLC bought a new position in Harrow in the 3rd quarter worth about $271,000. Brookstone Capital Management purchased a new position in Harrow in the 4th quarter worth approximately $275,000. Finally, Bleakley Financial Group LLC raised its position in Harrow by 63.1% during the fourth quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company’s stock valued at $294,000 after purchasing an additional 3,394 shares in the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Stock Up 3.0 %

HROW opened at $28.09 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a twelve month low of $9.86 and a twelve month high of $59.23. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -29.88 and a beta of 0.69. The firm has a 50 day moving average price of $29.67 and a 200-day moving average price of $38.48.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HROW. B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Harrow in a report on Tuesday.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.